To address these needs,
Eligo is developing a new class of
targeted biotherapeutic agents to selectively intervene on the microbiome.

We are using proprietary methods in synthetic biology, protein and genome engineering to create Eligobiotics: genetic circuits packaged in phage-based delivery vectors used to diagnose, eradicate, or functionalize targeted microbial populations.

 “Eligo’s technology could be as important as the discovery of penicillin.”  

– Professor Christian Brechot,
Executive director at Institut Pasteur

We are hiring!

Join Our Team